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Introduction elderly patients with mild disease or conversely 
An enormous amount has been written regarding 
the classification, prognosis and treatment of crypto- 
genie fibrosing alveolitis (CFA); (syn. idiopathic 
pulmonary fibrosis). However, the underlying aetiol- 
ogy remains unknown and the perceived poor results 
of treatment are mirrored by a nihilistic clinical 
approach to securing an accurate tissue diagnosis (1). 
These problems have probably contributed to a lack 
of progress in the medical management of CFA. 
However, high resolution computed tomography 
(HRCT) (2,3), video-assisted thorascopic (VATS) 
lung biopsy (3), and lung transplantation have repre- 
sented substantial advances in the management of 
these patients. To evaluate the current status of the 
response to medical treatment of CFA, one must 
first focus on the natural history of the untreated 
condition. 
The Natural History of CFA 
The interpretation of studies on the natural history 
of CFA is difficult, as most studies come from 
tertiary care centres where there is necessarily a 
selection bias in the patients studied. These studies 
suggest that the prognosis of CFA is poor and is 
similar to the survival of some solid organ tumours 
with only 50% of patients surviving 4 yr without 
treatment (45). However, as Scadding emphasized, 
CFA is a disease with a diverse natural history, some 
patients have a relatively benign course (6). Histo- 
logical definition is particularly important in the 
context of the natural history of the condition, but as 
CFA is a disease of the elderly, in many studies there 
may have been a bias not to obtain tissue from 
patients with severe disease. Indeed in the U.K., as 
many as 50% of patients die without ever having seen 
a respiratory specialist (1). Recently, the introduction 
of VATS lung biopsy has greatly assisted in reducing 
the morbidity of open lung biopsy, meaning that 
representative tissue is more easily obtained. Un- 
fortunately, VATS lung biopsy is generally only 
available in tertiary care centres. 
Histblogical Status 
When biopsy material is available, the histological 
pattern does seem to have some predictive value. 
Histologically, CFA may be viewed as a spectrum 
ranging from usual interstitial pneumonia (UIP), 
characterized by alveolar wall thickening with a 
variable interstitial infiltrate and severe remodelling 
of the lung by fibrosis, through to desquamative 
interstitial pneumonia (DIP) which is characterized 
by marked intra-alveolar macrophage accumulation 
and little fibrosis. What is unclear is whether these 
are just different histological features of the same 
disease at different chronological stages in its 
evolution or two entirely separate conditions (7). 
It is apparent that DIP has a better overall outlook 
than UIP (7). In a study of 40 DIP patients and 53 
UIP patients, the mean survival was 12 and 5 yr, 
respectively. Of the DIP patients, 20% improved 
spontaneously and 60% improved with steroid 
therapy compared to UIP patients of whom only 11% 
improved with treatment and 70% worsened. This 
data combined with the experience in the authors’ 
centre, which is that UIP is much more common than 
DIP, suggests that DIP is a unique and separate 
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potentially reversible, phase of CFA (8,9). However, 
this interpretation is complicated by the fact that 
CFA can be a patchy disease with variable histologi- 
cal features in a single open lung biopsy. As repre- 
sentative lung tissue can be difficult to obtain and 
because of the clinical heterogeneity of the condition, 
surrogate markers for disease activity and treatment 
response have been sought. 
Surrogate Markers of Disease Progression 
Clinicians recognize the variability in the rate of 
disease progression amongst patients within the 
heterogeneous syndrome of CFA. On this basis, most 
adopt a pragmatic strategy of sequential clinical 
observation using lung physiology, blood gas analy- 
sis and exercise capacity. However, lung physiology is 
a poor marker of disease status. For example, in a 
study of patients who failed to respond to conven- 
tional therapy and received pulsed cyclophospha- 
mide, the lung function of those who died was no 
different to those who survived (10). Lung physiology 
may also be influenced by the effects of smoking. In 
clinical trials, since CFA is a process which can affect 
patients from a wide age range, percent of predicted 
values of lung function are routinely used, but these 
are nevertheless difficult to interpret. The application 
of standardized residual values of lung physiology, 
which reduce the risk of hidden bias in population 
studies, may be more appropriate (11). 
Bronchoalveolar lavage (BAL) lymphocytosis has 
been reported to be associated with a favourable 
response to treatment. However, BAL lymphocytosis 
has not been sufficiently predictive to be clinically 
valuable. Promising new areas of progress in- 
clude exercise alveolar-arterial oxygen gradients (12) 
and inhaled 99”Tc-diethylenetriamine pentacetate 
(DTPA) scanning (13). However, DTPA scanning in 
particular needs further interdepartmental standardiz- 
ation. Finally, HRCT is the most encouraging marker 
for identifying patients with potentially reversible 
disease, and may facilitate substantial numbers of 
patients being included in therapeutic trials (14). How- 
ever, the authors believe the widespread application of 
HRCT should not counter a philosophy of addition- 
ally acquiring lung tissue for accurate histological 
characterization. This is important in view of the 
elusive aetiology of CFA and by virtue of the devel- 
opment of VATS lung biopsy, with its attendant low 
morbidity. 
Currently, the absence of a robust reproducible 
and quantifiable marker for disease activity and 
response to treatment has resulted in a reliance 
on mortality as the major primary outcome 
measure. 
Treatment Studies 
On the basis that CFA is an inflammatory process 
with concurrent remodelling of the lung by fibrosis 
(8,15), the natural choice for treatment has been the 
use of oral corticosteroids. However, the response to 
steroids is extremely variable, difficult to quantify 
and often only subjective. In Scadding’s original 
lecture describing 26 patients with CFA, 12 patients 
had received corticosteroid therapy (6). Of these, 
three patients had an objective response to treatment, 
four patients only had a subjective response to 
steroids, and the remainder deteriorated. In a retro- 
spective analysis of 127 patients from the Brompton 
Hospital, treated with steroids and followed for at 
least 4 yr, only 17% showed an objective response to 
treatment (16). In that study, a good response to 
steroids appeared to influence survival and further 
identified a subgroup of patients with a better prog- 
nosis, who were younger and had a more cellular 
(UIP) lung biopsy. 
Only two controlled studies have addressed the 
issue of response to treatment (17,18). Johnson et al. 
compared 22 patients treated with prednisolone alone 
(60 mg daily for 30 days, decreasing by 5 mg weekly 
to a maintenance of 20 mg on alternate days) with 21 
patients treated with cyclophosphamide (lo&120 mg 
daily) plus low dose prednisolone (20 mg alternate 
days) (17). The major endpoints were change in lung 
physiology and survival. Patients were allowed to 
switch between the limbs of the trial because of lack 
of treatment response; 56% of patients did so, of 
which two-thirds were in the prednisolone group. 
Unfortunately the study groups were unbalanced 
prior to treatment, with the ‘prednisolone-alone’ 
group having 40% of patients with a total lung 
capacity of less than 60% predicted in comparison to 
only 14% of the cyclophosphamidelprednisolone 
group. This disparity in patient physiology at entry 
also contributes to the more favourable survival 
outcome for the cyclophosphamide/prednisolone 
group. However, a log rank survival analysis did not 
demonstrate a statistically significant benefit for 
either treatment group. 
Raghu et al. evaluated 27 patients in a double- 
blind randomized placebo-controlled fashion (18). 
This study compared 13 patients treated with pred- 
nisolone plus placebo (1.5 mg kg - ’ day - ’ for 2 
weeks tapering every second week to a maintenance 
of20mgkgg’ day- ‘) to 14 patients treated with an 
identical prednisolone regiment plus azathioprine 
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(3 mg kg - ‘day- ‘). Forty-eight percent of the 
patients died from progressive respiratory failure dur- 
ing the study. Although there was a suggestion of 
improvement in lung physiology in the prednisolone/ 
azathioprine group, there was no difference in survival. 
When the survival analysis was adjusted for age, there 
appeared to be a marginally significant improvement 
survival in the azathioprine/prednisolone group in 
comparison to prednisolone alone. Using a Cox model 
survival analysis, the P value (P=O.O5) was based on a 
randomization test in order to correct for small num- 
bers. Whilst this needs to be interpreted with caution in 
this small study, it did demonstrate that the additional 
use of azathioprine had no excess drug toxicity but the 
clinical benefit was not substantial. 
These two studies are important because they 
exemplify the difficulties of achieving meaningful 
therapeutic studies in CFA. The small numbers 
reflect appropriate efforts to study patients with 
biopsy-proven CFA and have clinically uniform 
patients in each treatment group. However, the small 
numbers of evaluable patients with a heterogeneous 
disease have low power to detect small changes in 
endpoints and there is a risk that the patient groups 
will be unbalanced at the start. 
Failure to respond to steroids is often used as an 
indication for second line immunosuppression. 
Cyclosporin is an efficient T-cell suppressor and on 
the basis of the important role lymphocytes play in 
the inflammatory response, it is an attractive thera- 
peutic agent. Two open non-randomized studies have 
evaluated cyclosporin in small groups of patients. 
Moolman et al. reported the effects of cyclosporin in 
five patients with CFA and another five patients with 
non-specific interstitial fibrosis, eight of whom had 
previously received steroids (19). The cyclosporin was 
only administered for a set period of 9 months. Three 
CFA patients were reported as responding. Alton 
et al. used a once-daily dose of 5 mg kg - ’ day - ’ in 
seven patients who had failed a cyclophosphamide/ 
prednisolone combination treatment regimen (20). 
These patients had severe disease but there was a 
suggested survival improvement of 2.5-5 months in 
the treatment group. An improved strategy might 
include higher doses of cyclosporin monitored by 
serum levels, with a more optimal pharmacokinetic 
twice-daily dosage at an earlier stage of the disease. 
Colchicine in vitro has been shown to block the 
release of fibronectin and macrophage-derived 
growth factors; cytokines involved in fibroblast pro- 
liferation (21). In vivo colchicine is well tolerated in 
appropriate doses. In a retrospective analysis of data 
from 23 patients treated with colchicine, 18 of whom 
received steroid therapy in addition, it was reported 
that 20% of patients improved, 40% remained stable 
and 40% deteriorated (22). At first glance, this data 
appears encouraging but it is complicated by the 
additional use of steroids and is probably no different 
from the results seen in patients treated with steroids 
alone. This therapy has not been followed-up with 
enthusiasm. 
Penicillamine has properties which block collagen 
cross-links and therefore might be a beneficial 
agent. Prednisolone alone (40 mg day- i tapering to 
20 mg maintenance, n= 11) has been compared 
to two groups who received an identical steroid 
regimen in addition to either D-penicillamine at a 
dose of 1800 mg day- ’ (n= 11) or azathioprine 
(3mgkgg’day-‘, n=15). In this study, there was 
a high rate of side-effects (nephrotic syndrome) in 
the penicillamine group and no benefit was 
observed (23). 
An Alternative Philosophy is Required 
But why are steroids alone and in combination 
with other agents apparently less than optimal 
therapy? Firstly, most non-responders may be 
patients in whom lung remodelling (i.e. fibrosis) is 
established and irreversible. Secondly, steroids have 
little effect on cytokines involved in fibroblast prolif- 
eration (24,25). Thirdly, non-responders may have 
coexisting pulmonary pathology, especially emphy- 
sema. These factors argue for early specialist referral, 
aggressive investigation and treatment in order to 
target patients prior to the development of severe 
fibrosis. Additionally in the presence of fibrosis, the 
absence of disease progression must become an 
acceptable therapeutic goal. 
No magical solution for the treatment of CFA is 
offered by any single drug treatment. The application 
of drugs in uncontrolled studies with small numbers 
of patients results in great difficulty in evaluating any 
clinical efficacy. Combination therapy with 3-5 
agents at an early stage of disease may be required 
for maximum potential benefit, but selecting which 
drugs and devising studies of adequate power will 
require a major multi-centre effort. Several new 
potentially important agents such as gluthathione, 
pirfenidone, IL-4, antiproteinases, cytokine inhibi- 
tors and gene therapy, in time are set to move from 
the bench to the bedside (26). However, evaluation of 
all these agents will require adequately powered 
randomized studies with acceptable markers for 
disease activity and agreed endpoints. 
Conclusion 
Cryptogenic fibrosing alveolitis is a heterogeneous 
disease with a generally poor prognosis. Steroids 
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alone give an objective response in only one-fifth of 
patients. Additional immunosuppressive drugs may 
give some small additional benefit, but the majority 
of studies are either small, retrospective or both. 
Further progress will only be made by an aggressive 
approach to early tissue diagnosis, the validation of 
robust reproducible surrogate markers of disease 
activity, large controlled trials of combinations of 
agents, and further insights into causation. Thera- 
peutic trials for CFA have been ongoing for almost 
40 yr, with depressingly little benefit for our patients 
as yet. 
Acknowledgements 
The authors wish to thank Drs B. Bradley and 
K. B. Carroll for their useful comments. 
References 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
Johnston IDA, Gomm SA, Kalra S, Woodcock AA, 
Evans CC, Hind CRK. The management of crypto- 
genie fibrosing alveolitis in three regions of the United 
Kingdom. Eur Respir J 1993; 6: 891-893. 
Wells AU, Du Bois RM. Predictor of disease progres- 
sion in idiopathic pulmonary fibrosis. Eur Respir J 
1994; 7: 637-639. 
Raghu G. Interstitial lung disease: a diagnostic 
approach. Am J Respir Crit Care Med 1995; 151: 
909-914. 
Stack BHR, Choo-Kang YFJ, Heard BE. The progno- 
sis of cryptogenic fibrosing alveolitis. Thorax 1972; 27: 
535-542. 
Turner-Warwick M, Burrows B, Johnson A. Crpyto- 
genie fibrosing alveolitis: clinical features and their 
mfluence on survival. Thorax 1980; 35: 17ll180. 
Scadding JG. Diffuse interstitial fibrosis of the lung. 
BMJ 1960; 1: 443450. 
Carrington CB, Gaensler EA, Coutu RE, Fitzerald 
MX, Gupta RG. Natural history and treated course of 
usual and desquamative interstitial pneumonia. N Engl 
J Med 1978; 2%~ 801-809. - 
McDonald JA. Idiopathic pulmonarv fibrosis, a 
paradigm for lung injury and-repair. dhest 1991; 99: 
87S-93s. 
Cherniack RM. Colby TV, Flint A et al. Correlation of 
structure and function in idiopathic pulmonary fibrosis. 
Am J ResDir Crit Care A4ed 1995: 151: 1180-1188. 
Dayton CS, Schwartz DA, Helmers RA et al. Outcome 
of subjects with idiopathic pulmonary fibrosis who fail 
corticosteroid therapy, Implications for future studies. 
Chest 1993; 103: 69-73. 
Miller MR, Pincock AC. Predicted values: how should 
we use them? Thorax 1988; 43: 2655267. 
Agusti C, Xaubet A, Agusti AGN, Rota J, Ramirez J, 
Rodriguez-Rosin R. Clinical and functional assessment 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
of patients with idiopathic pulmonary fibrosis: results of 
a 3 year follow up. Eur Respir J 1994; 7: 643-650. 
Wells AU, Hansel1 DM, Harrison NK, Lawrence R, 
Black SM, Du Bois RM. Clearance of inhaled 99mTc- 
DTPA predicts the clinical course of fibrosing alveolitis. 
Eur Resp J 1993; 6: 797-802. 
Wells AU, Hansel1 DM, Rubens MB, Cullinan P, Black 
CM, DuBois RM. The predictive value of appearances 
on thin-section computed tomography in fibrosing 
alveolitis. Am Rev Respir Dis 1993; 148: 10761082. 
Kuhn C, Boldt J King TE, Crouch E, Varito T, 
McDonald JA. An immunohistochemical study of 
architectural remodelling and connective tissue syn- 
thesis in pulmonary fibrosis. Am Rev Respir Dis 1989; 
140: 1693-1703. 
Turner-Warwick M, Burrows B, Johnson A. Crypto- 
genie fibrosing alveolitis: response to corticosteroid 
treatment and its effect on survival. Thorax 1989; 35: 
593-399. 
Johnson MA, Kwan S, Snell NJC, Nunn AJ, 
Darbyshire JH, Turner-Warwick M. Randomised 
controlled trial comparing prednisolone alone with 
cyclophosphamide and low dose prednisolone in com- 
bination in cryptogenic fibrosing alveolitis Thorax 1989; 
44: 280-288. 
Raghu G, Depaso WJ, Cain K et al. Azathioprine 
combined with prednisolone in the treatment of idio- 
pathic pulmonary fibrosis: a prospective double-blind, 
randomised, placebo controlled clinical trial. Am Rev 
Respir Dis 1991; 144: 291-296. 
Moolman JA, Bardin PG, Rossouw DJ, Joubert JR. 
Cyclosporin as a treatment for interstitial lung disease 
of unknown aetiology. Thorax 1991; 46: 592-595. 
Alton EWF, Johnson M, Turner-Warwick M. 
Advanced cryptogenic fibrosing alveolitis: preliminary 
report on treatment with cyclosporin A. Respir Med 
1989; 83: 2777279. 
Rennard SI, Bitterman PB, Ozaki T, Rom WN, Crystal 
RG. Colchicine suppresses the release of fibroblast 
growth factors from alveolar macrophages in vitro. Am 
Rev Respir Dis 1988; 137: 181-185. 
Peters SG, McDougall JC, Douglas WW, Coles DT, 
DeRemeee RA. Colchicine in the treatment of pul- 
monary fibrosis. Chest 1993; 103: 101-104. 
Meier-Sydow J, Rust M, Kronenberger H, Krempel S. 
Survival of patients with idiopathic pulmonary fibrosis 
following treatment with azathioprine, d-penicillamine 
or prednisoline ten year follow-up. Chest 1990; 94: 18s. 
Kelley J. Cytokines of the lung. Am Rev Respir Dis 
1990; 141: 765-788. 
Lacronique JG, Rennard SI, Bitterman PB, Ozaki T, 
Crystal RG. Alveolar macrophages in idiopathic 
pulmonary fibrosis have glucocorticoid receptors, but 
glucocorticoid therapy does not supress alveolar macro- 
phage release of fibronectin and alveolar macrophage 
derived growth factor. Am Rev Respir Dis 1984; 130: 
450-456. 
Hunninghake GW, Kalica AR. Approaches to treat- 
ment of pulmonary fibrosis. Am J Respir Crit Care Med 
1995; 151: 915-918. ’ 
